Hot Investor Mandate: Newly Established US-based VC Looks for Early-stage Medtech and Digital Health Companies, Focused on US-based Companies but Open to Global

18 May

A newly established venture capital firm based in the USA  just successfully closed the first round of their fund ($20M target), and made its first investment. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Over 50 Companies Pitching at RESI Boston June 2023

11 May

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

With about a month left until RESI Boston June 2023 and a few days before partnering launch, LSN is very excited to announce the list of 50+ finalist companies who will be participating in the Innovator’s Pitch Challenge (IPC)!

The deadline was set earlier than our usual IPC application cycles, but the RESI team still received a record number of applications.

Over 50 companies representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools across the globe will be delivering a live pitch followed by a Q&A session with a panel of investors and industry experts. In addition, the companies will be presenting a poster showcasing their technology in the exhibit hall. We were very impressed by all of the amazing technologies developed by the IPC finalist companies and we cannot wait to showcase them at the upcoming RESI!

Below are the participating companies. If you are interested in seeing these pitches and engaging in one-on-one partnering with over 1,000 attendees expected to attend, you can register here!

RESI Boston June 2023 IPC Finalists

RESI-Boston-2023-June-1100px

Partnering Opens Next Week

11 May

By Caitlin Dolegowski, Marketing Manager, LSN

RESI Boston, June 5-7 is rapidly approaching, and the partnering platform opens next Monday, May 15. This hybrid conference enables attendees to book meetings either in person on Monday, June 5, or virtually, June 6-7.  The LSN Partnering Platform offers startups the opportunity to search for and identify investors that are a fit for them based on sector, indication, stage of development and other criteria. Successful partnering takes a lot of work, and the companies that book the most meetings send, on average, over 100 meeting requests to relevant investors, followed by frequent follow-ups. We will be offering a free partnering tutorial next week to provide you with helpful insight into making the most of your time at RESI.

There is still time to register for RESI Boston, June 5-7 and meet with 350+ active investors in the life science industry.

RESI-Boston-2023-June-1100px

See Who’s Exhibiting at RESI Boston

11 May

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI Boston during BIO week is just a few weeks away. We’ve already told you about the opportunity to meet with 350+ investors and licensing partners and amazing panels and workshops, but you will also be able to meet with some top service providers who may have just the product or service your company needs or will need in the future. RESI is the conference for early-stage partnering, where you can make connections that are focused on this space that you won’t find at other conferences that are geared toward later stage activities.

Here are some of the companies you can meet in the RESI Exhibition Hall this June.

See you in Boston! REGISTER HERE
RESI-Boston-2023-June-1100px

Hot Investor Mandate: Global Investment Firm Focusing on Oncology Therapies Invests Up to $30M Over the Company’s Lifecycle

11 May

A global investor, headquartered in Western Europe with no geographical restrictions, is actively seeking new investment opportunities. The firm is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic diseases. The firm makes selective investments in newly founded or early-stage companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. Typically, the firm invests in incorporated companies from seed stage onwards, and it can invest $25-30M over the lifetime of the companies. Currently, the firm is raising its fourth fund which in addition to its core strategy to invest in early stage companies, will also be used to invest in late stage financings, cross-over financings, IPO’s, and listed stock. These companies can either be portfolio companies or external companies.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies and therapeutics targeting genetic diseases, and is open to all types of therapeutic modalities and all indications relevant to those spaces, including platform technologies. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Projects will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

At its core, the firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of its portfolio companies. To this end, the firm has several experts in oncology and genetic diseases, intellectual property, and drug development on the investment team which are available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm With US & Asia Offices Seeks New Investments in Medical Devices, Synthetic Biology, and Digital Health

11 May

A venture capital firm based in Singapore, with an additional office in the US makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and digital health. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.

The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Arm of Large Corporation Invests in Accountable Care-Centered Solutions, Targeting the USA Market

11 May

With multiple offices throughout the US, a new business unit within a large corporation is focused on improving the quality, affordability and equity of employer-sponsored health care. This new investment arm is investing from the corporate’s balance sheet in early-stage and advanced health companies that offer accountable care and value-based solutions to employers and employees.

The firm’s “sweet spot” is in Series B and beyond. While the organization primarily deploys growth equity capital, it can consider making investments into earlier stage companies. The firm can invest in, and will consider opportunities outside of the U.S. market, but these opportunities must be focused on the employer-sponsored insurance market in the U.S.

Within healthcare, the firm invests primarily in accountable care-centered solutions and integrated disease management programs. The firm’s core focus areas are care delivery, priority conditions, analytics & enablers of advanced medical care, and pharma services.

The firm is also focused on health solutions that can be implemented in a remote or at-home setting, reducing the burden of patients. In terms of stage of development, the firm expects to see customer traction and revenue generation taking place – companies who are still developing a working product that has yet to be implemented will generally be considered too early for investment.

The firm seeks to invest in companies that have established substantial validation on their product/technology. The firm has board representation with each of the companies it has invested in and has typically served as a syndicate partner to lead investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →